Ascentage Pharma Group International (AAPG) Competitors $18.70 +1.00 (+5.65%) As of 04/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock AAPG vs. ROIV, LNTH, LEGN, BBIO, TGTX, RVMD, SRPT, BPMC, KRYS, and AXSMShould you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Roivant Sciences (ROIV), Lantheus (LNTH), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Revolution Medicines (RVMD), Sarepta Therapeutics (SRPT), Blueprint Medicines (BPMC), Krystal Biotech (KRYS), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Ascentage Pharma Group International vs. Roivant Sciences Lantheus Legend Biotech BridgeBio Pharma TG Therapeutics Revolution Medicines Sarepta Therapeutics Blueprint Medicines Krystal Biotech Axsome Therapeutics Ascentage Pharma Group International (NASDAQ:AAPG) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings. Do analysts rate AAPG or ROIV? Roivant Sciences has a consensus target price of $17.50, suggesting a potential upside of 77.48%. Given Roivant Sciences' higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, AAPG or ROIV? Roivant Sciences has lower revenue, but higher earnings than Ascentage Pharma Group International. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscentage Pharma Group International$980.65M1.66N/AN/AN/ARoivant Sciences$122.59M57.39$4.35B-$0.15-65.73 Does the media refer more to AAPG or ROIV? In the previous week, Roivant Sciences had 5 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 8 mentions for Roivant Sciences and 3 mentions for Ascentage Pharma Group International. Roivant Sciences' average media sentiment score of 1.49 beat Ascentage Pharma Group International's score of 1.04 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is AAPG or ROIV more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Ascentage Pharma Group International's return on equity of 0.00% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group InternationalN/A N/A N/A Roivant Sciences -119.54%-14.05%-12.81% Does the MarketBeat Community prefer AAPG or ROIV? Roivant Sciences received 53 more outperform votes than Ascentage Pharma Group International when rated by MarketBeat users. However, 100.00% of users gave Ascentage Pharma Group International an outperform vote while only 78.26% of users gave Roivant Sciences an outperform vote. CompanyUnderperformOutperformAscentage Pharma Group InternationalOutperform Votes1100.00% Underperform VotesNo VotesRoivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% Do institutionals and insiders believe in AAPG or ROIV? 64.8% of Roivant Sciences shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryRoivant Sciences beats Ascentage Pharma Group International on 9 of the 14 factors compared between the two stocks. Remove Ads Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AAPG vs. The Competition Export to ExcelMetricAscentage Pharma Group InternationalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.63B$6.23B$5.25B$7.52BDividend YieldN/A3.04%5.34%4.30%P/E RatioN/A6.6321.3617.69Price / Sales1.66218.18366.3293.44Price / CashN/A65.6738.1534.64Price / BookN/A5.716.283.89Net IncomeN/A$141.10M$3.19B$247.17M7 Day Performance-10.74%0.11%0.66%1.77%1 Month Performance0.38%-16.19%-11.10%-8.64%1 Year PerformanceN/A-18.28%4.51%-4.07% Ascentage Pharma Group International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AAPGAscentage Pharma Group InternationalN/A$18.70+5.6%N/AN/A$1.63B$980.65M0.00600Positive NewsGap UpROIVRoivant Sciences2.202 of 5 stars$9.46-5.5%$17.50+85.0%N/A$6.75B$122.59M-63.06860Positive NewsGap DownLNTHLantheus4.252 of 5 stars$90.92-6.5%$129.43+42.4%N/A$6.23B$1.53B15.13700Positive NewsLEGNLegend Biotech2.6254 of 5 stars$32.01-2.6%$79.00+146.8%N/A$6.04B$627.24M-33.691,070Analyst ForecastNews CoveragePositive NewsBBIOBridgeBio Pharma4.5334 of 5 stars$31.37-7.9%$52.64+67.8%N/A$5.97B$221.90M-11.01400Positive NewsTGTXTG Therapeutics3.2512 of 5 stars$37.35-5.1%$40.67+8.9%N/A$5.87B$329.00M-373.46290News CoveragePositive NewsRVMDRevolution Medicines3.5042 of 5 stars$31.32-4.7%$65.23+108.3%N/A$5.82B$742,000.00-8.72250Analyst ForecastPositive NewsSRPTSarepta Therapeutics4.7876 of 5 stars$54.43-7.1%$163.18+199.8%N/A$5.28B$1.90B43.54840Quiet Period ExpirationNews CoverageHigh Trading VolumeBPMCBlueprint Medicines2.5384 of 5 stars$81.68-6.2%$124.95+53.0%N/A$5.22B$508.82M-75.63640Analyst ForecastPositive NewsGap DownHigh Trading VolumeKRYSKrystal Biotech4.7956 of 5 stars$171.30-3.8%$220.00+28.4%N/A$4.93B$290.52M57.29210News CoverageAXSMAxsome Therapeutics4.5018 of 5 stars$98.86-8.4%$167.64+69.6%N/A$4.82B$385.69M-16.50380Analyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies ROIV Alternatives LNTH Alternatives LEGN Alternatives BBIO Alternatives TGTX Alternatives RVMD Alternatives SRPT Alternatives BPMC Alternatives KRYS Alternatives AXSM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AAPG) was last updated on 4/13/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and s...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
